SCHEMBL100480

SCHEMBL100480

CCc1nc2c(N3CCOCC3)nc(SCc3ccc(OC)c([N+](=O)[O-])c3)nc2n1C

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.47
CYP2C19 P33261 2/20 0.45
CYP1A2 P05177 1/20 0.45
LMNA P02545 3/20 0.43
MAPT P10636 3/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
GFER P55789 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
PIK3CA P42336 1/20 0.42
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MAPK1 P28482 1/20 0.39
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1619243 0.90 PIK3CA (0.43) ALDH1A1CYP2C19CYP1A2LMNAMAPT
SCHEMBL95758 0.88 PIK3CA (0.46) ALDH1A1LMNAPIK3CAGAAHTT
SCHEMBL97744 0.87 PIK3CA (0.45) ALDH1A1CYP2C19CYP1A2LMNAMAPT
SCHEMBL98098 0.86 PIK3CA (0.49) ALDH1A1LMNAPIK3CAGAAHTT
SCHEMBL98394 0.86 ALDH1A1 (0.45) ALDH1A1LMNASMN1; SMN2PIK3CAGAA
SCHEMBL97915 0.86 ALDH1A1 (0.46) ALDH1A1LMNAMAPTHPGDGFER
SCHEMBL98503 0.86 PIK3CA (0.44) ALDH1A1LMNAPIK3CAGAAHTT
SCHEMBL1679999 0.85 PIK3CA (0.43) ALDH1A1LMNAPIK3CAGAAHTT
SCHEMBL99312 0.85 PIK3CA (0.43) ALDH1A1LMNAPIK3CAGAAHTT
SCHEMBL97922 0.85 PIK3CA (0.43) ALDH1A1LMNAHPGDPIK3CAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US disclosed
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US disclosed
EP-2426130-B1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KK (JP) 2015-03-11 EP disclosed
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-04-12 US disclosed
EP-2426130-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-03-07 EP disclosed
WO-2010126101-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME 全薬工業株式会社 (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME PNP, TYMP, DPYD ALDH1A1 336/4885CYP2C19 1540/4885CYP1A2 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.